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Introduction: Siliceous nanoparticles (NPs) have been extensively studied in nanomedicine 
due to their high biocompatibility and immense biomedical potential. Although numerous tech-
nologies have been developed, the synthesis of siliceous NPs for biomedical applications mainly 
relies on a few core technologies predominantly intended to produce spherical-shaped NPs. 
Methods: In this context, the impact of different morphologies of siliceous NPs on biodistribu-
tion in vivo is limited. In the present study, we developed a novel technique based on an aerosol 
silane reactor to produce sintered silicon NPs of similar size but different surface areas due 
to distinct spherical subunits. Silica-converted particles were functionalized for radiolabeling 
with copper-64 (64Cu) to systematically analyze their behavior in the passive targeting of A431 
tumor xenografts in mice after intravenous injection.
Results: While low nonspecific uptake was observed in most organs, the majority of particles 
were accumulated in the liver, spleen, and lung. Depending on the morphologies and function-
alization, significant differences in the uptake profiles of the particles were observed. In terms 
of tumor uptake, spherical shapes with lower surface areas showed the highest accumulation 
and tumor-to-blood ratios of all investigated particles.
Conclusion: This study highlights the importance of shape and fuctionalization of siliceous 
NPs on organ and tumor accumulation as significant factors for biomedical applications.
Keywords: silicon, silica, human tumor xenograft, PEGylation, 64Cu
Introduction
Nanoparticle (NP) research has emerged as one of the top scientific fields due to the 
unique properties of nanomaterials with tremendous potential use in medicine and other 
fields.1,2 In contrast to traditionally used bulk materials, NPs possess unique biochemi-
cal, electronic, magnetic, and optical properties that rely on their sub-micrometer size 
(,1 µm) and their high surface-to-volume ratio.3 Nanoscale materials have now entered 
clinical trials with more than 100 agents being evaluated or approved by the US Food 
and Drug Administration.4 The current clinical nanomedicine approaches investigate 
many different diseases (ClinicalTrials.gov) but mainly focus on the imaging and treat-
ment of cancer.5,6 Compared to most traditional therapeutics, NP-based drug delivery 
systems (DDSs) facilitate the fine-tuning of many important properties influencing the 
drug pharmacokinetics including solubility, circulation time, and target-specific distri-
bution.7 Although current commercial nanodrugs are still single functional, NPs can be 
engineered as multifunctional systems allowing several functions at the same time, eg, 
specific targeting, controlled drug release, and in vivo imaging.8 However, integrating 
several nanomaterials into one multifunctional system remains challenging and is the 
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subject of intensive research.9 Nevertheless, much preclinical 
research is focused on the development of multifunctional 
agents to merge therapeutic and diagnostic modalities in one 
single compound and thus bring us closer to the long-conceived 
dream of “theranostics”.10,11
The immense interest in nanomedicine led to the develop-
ment of numerous DDSs including micelles, liposomes, pro-
teins, dendrimers, and polymers.12 Last but not least, inorganic 
materials have been studied for their potential use in nano-
medicine since they offer advantages in terms of synthesis and 
stability.13 Most of the inorganic materials in nanomedicine 
are either based on noble metals or based on metal oxides, 
but concerns about the toxicity of some of these compounds 
arose and are subject of intense discussion.14–17 A special class 
of inorganic nanomaterials is based on semiconductor silicon 
(Si) and its oxide silica (Si dioxide [SiO
2
]).18–21 Siliceous 
materials have been studied as inorganic alternatives with low 
toxicity for nanomedicine due to their high biocompatibility 
and nontoxic degradation products, eg, nontoxic silicic acid 
that is rapidly excreted by the kidneys.22
Nowadays, silica NPs (SiO
2
NPs) are the best-investigated 
class of siliceous nanomaterial in biomedicine due to their high 
biocompatibility, degradability, tunable morphology, and ease 
of modification.20–23 Moreover, silica can be integrated with 
other nanomaterials to achieve multifunctionality, eg, by coat-
ing other inorganic materials such as gold and iron oxide to pro-
duce core–shell NPs.24 As a most prominent example, Cornell 
dots (C-dots) possess a fluorescent core and represent the first 
SiO
2
NPs under clinical investigation.25,26 Biomedical SiO
2
NPs 
are typically produced by various bottom-up approaches where 
precursor particles grow in size via chemical reactions. Most of 
the current approaches are based on sol–gel methods evolved 
from the Stöber process introduced in 1968.27 This approach 
allows the production of monodisperse silica particles in vary-
ing sizes (5–2,000 nm) by the hydrolysis and condensation of 
silanes in aqueous solution and in the presence of a mineral 
acid or base as catalyst. By adding surfactants to the process, 
pores of different shapes and sizes can be integrated into the 
silica network. This allows the generation of mesoporous 
SiO
2
NPs with high surface areas that are promising platforms 
for robust and controllable drug delivery.28 Recently, a new 
class of silica hybrid analogs has emerged, using various 
organosilica precursors during the sol–gel synthesis. These 
(periodic) mesoporous organosilica NPs contain organic 
bridges in their silica network that facilitates the functionaliza-
tion for biomedical applications.21
The other class of siliceous nanomaterial being investi-
gated in biomedicine is based on elemental Si.19 In general, 
biomedical Si NPs (SiNPs) are characterized by a fast 
hydrolytic in vivo degradation and renal clearance.22 Porous 
Si (pSi) NPs are fabricated in various top-down approaches 
relying on etching and milling. Most frequently electrochemi-
cal etching of the surface of a Si wafer is used to produce both 
spherical-shaped and irregularly shaped pSi.29,30 Recently, pSi 
NPs have received attention as promising multifunctional plat-
forms for drug delivery and noninvasive imaging due to high 
drug loading capacity and adjustable pore sizes.19 Although 
thin layers of native oxide are usually observed, pSi NPs are 
often oxidized in controlled conditions to produce defined 
layers of SiO
2
 of varying thicknesses to archive higher in 
vivo stability, improved functionalization, and better drug 
release.19,29 In terms of imaging, oxidized pSi NPs exhibit 
intrinsic near-infrared photoluminescence due to quantum 
confinement effects and defects at the Si–SiO
2
 interface, 
which can be used for in vivo tracking.31 In contrast, this intrin-
sic luminescence of pSi NPs is rapidly lost under physiological 
conditions and other imaging technologies such as MRI, PET, 
and SPECT have successfully been implemented.24 In contrast 
to pSi, nonporous SiNPs can be typically produced by numer-
ous technologies including both top-down and bottom-up 
approaches but also mixtures of both involving decomposition 
and re-assembly of precursors.32 Currently, these approaches 
are predominantly used to synthesize smaller (2–8 nm), col-
loidal quantum dots (QDs), which are highly attractive for in 
vitro and in vivo imaging applications due to their low toxicity 
compared to conventional heavy metal QDs.33
In this article, we implemented a novel aerosol reactor-
based approach to produce various siliceous NPs for 
potential biomedical applications. First, nonporous SiNPs 
were synthesized by thermal decomposition of silane in an 
aerosol reactor. By adjusting the reactor conditions, we could 
control the synthesis process to produce three differently 
shaped SiNPs of similar final size (~170 nm) but consisting 
of differently sized smaller primary particles. Outer layers of 
these SiNPs were converted by thermal oxidation into SiO
2
 to 
obtain higher biostability in vivo. To analyze their biomedi-
cal potential, the functionalized NPs were radiolabelled with 
copper-64 (64Cu) and injected in tumor-bearing mice. For 
comparison, in vivo studies were done in parallel with spheri-
cal SiO
2
NP of similar size that was produced by a standard 
sol–gel approach. Biodistribution of both polyethylene glycol 
(PEG)ylated and non-PEGylated NPs was analyzed after 4 
and 24 hours of circulation and tissue uptake discussed in 
light of morphology and functionalization. Our data show the 
value of these aerosol-synthesized Si–SiO
2
 nanocomposites 
for potential biomedical applications and give insight into 
the impact of morphology and functionalization of these NPs 
on in vivo organ distribution.
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Materials and methods
chemicals and reagents
All chemicals and reagents were purchased from commercial 
suppliers and used without further purification. Silane in 
helium (0.9% SiH
4
), helium, and nitrogen (all ultrahigh purity) 
were obtained from Airgas (Radnor, PA, USA) and used for 
synthesizing SiNPs in the gas phase. Ultrapure type I water 
(resistivity: 18.2 MΩ⋅cm) was obtained from an in-house 
PURELAB flex system from Evoqua Water Technologies 
(Pittsburgh, PA, USA). (3-Aminopropyl)-triethoxysilane 
(APTES, 99%), ammonium acetate (NH
4
OAc) ($99.99% 
trace metal basis), Chelex 100 sodium form, and dimethyl 
sulfoxide (DMSO, anhydrous, $99.9%) were purchased 
from Sigma-Aldrich Co. (St Louis, MO, USA). Absolute 
ethanol (200 proof) was bought from Decon Labs (King of 
Prussia, PA, USA), and ITLC-SG paper was bought from 
Agilent Technologies (Santa Clara, CA, USA). Chelator 
2-S-(4-isothiocyanatobenzyl)–1,4,7-triazacyclononane- 
1,4,7-triacetic acid (p-SCN-Bn-NOTA, $94%) was purchased 
from Macrocyclics (Plano, TX, USA), cross-linker MAL-
PEG-SCM (molecular weight: 5 kDa) was purchased from 
Creative PEGWorks (Chapel Hill, NC, USA), and diethyl-
enetriaminepentaacetic acid (DTPA, 98.5%) was purchased 
from Strem Chemicals (Newburyport, MA, USA). 64Cu 
(t
1/2
=12.7 hours, β+=17%, β-=39%, electron capture =43%, 
E
max
 =0.656 MeV) was produced by a (p,n) reaction on enriched 
64Ni on a TR-19 biomedical cyclotron (Advanced Cyclotron 
Systems Inc., Richmond, BC, Canada) at Mallinckrodt Insti-
tute of Radiology, Washington University School of Medi-
cine (WUSM) and purified with an automated system using 
standard procedures.34,35 For radiolabeling, a stock solution of 
64CuCl
2
 was diluted with a 10-fold excess of 0.1 M NH
4
OAc 
(pH 5.5). FBS, DMEM, PBS (1×), and trypsin-EDTA were 
obtained from Thermo Fisher Scientific (Waltham, MA, USA). 
Sterile, nonpyrogenic saline (0.9% sodium chloride injection) 
was purchased from Hospira (Lake Forest, IL, USA).
synthesis of aerosol-synthesized NPs
Nonspherical siliceous NPs (NP1, NP2, and NP3) were syn-
thesized via silane pyrolysis in a silane furnace aerosol reactor. 
The reactor was made of a stainless steel tube (1″ diameter and 
18″ long) inside a Lindberg Furnace (Thermo Fisher Scien-
tific). The reactor was fed by gas from three cylinders with a 
fixed chemical composition of silane in helium (0.9% SiH
4
), 
helium, and nitrogen. Mass flow controllers (MKS Instruments, 
Andover, MA, USA) were used to independently regulate the 
flow of each gas stream into the reactor. A pressure transducer 
(WIKA Instruments, Klingenberg am Main, Germany) was 
used to monitor pressure. Data acquisition and user interface 
were achieved via LabVIEW (National Instruments, Austin, 
TX, USA) and a data acquisition board (National Instru-
ments). NP1 was synthesized by feeding the reactor with 
0.004% silane, 19.021% helium, and 80.975% nitrogen using 
a reactor temperature of 1,000°C. Produced Si particles were 
collected on quartz filters (Advantec MFS, Dublin, CA, USA) 
for 10 hours during continuous reactor operation. NP2 and 
NP3 were produced in a similar way using 0.02% silane and 
99.98% helium under constant flow using temperatures for 
the silane pyrolysis of 600°C (NP2) or 1,000°C (NP3) and 
10 hours continuous reactor operation. Outer layers of SiNPs 
were converted into silica by thermal oxidation using particle-
specific conditions. NP1 was isothermally treated for 1 hour at 
900°C by increasing the temperature with 1°C/min up to 400°C 
and 5°C/min to the final temperature. NP2 was oxidized for 
5 minutes at 500°C. NP3 was heated for 10 hours at 600°C, 
followed by 10 hours at 900°C. Right before further experi-
mentation, NPs were diluted in ultrapure water to 0.9 mg/mL 
(ie, 15 mM) and well-dispersed by ultrasonic treatment.
synthesis of spherical NPs
Spherical NP4 was synthesized using a sol–gel method 
following the procedure outlined by Möller and Bein.36 
To synthesize, 4 mL of absolute ethanol and 2 mL of ultrapure 
water were combined in a 50 mL glass vial and sonicated for 
3 minutes at room temperature (RT) using a bath sonicator. 
While maintaining sonication, 200 µL of tetraethyl ortho-
silicate (TEOS) was pipetted to the solution and sonicated 
for an additional 3 minutes. After the addition of 0.5 mL of 
ammonium hydroxide (NH
4
OH), the solution was sonicated 
for an additional 7–12 minutes and NP4 was separated by 
centrifugation. The supernatant was discarded, and the vials 
were kept at 60°C in an oven for 1 hour to get SiO
2
NPs in 
powdered form. NP4 was treated and stored as described 
earlier for aerosol-synthesized particles.
Surface modification of NPs with amines
The silica surface of the NPs was functionalized with amine 
groups by treatment with APTES. Typically, 60 µmol of NPs 
was centrifuged (16,800× g, 10 minutes) and resuspended 
in 7.6 mL of 5% H
2
O diluted in absolute ethanol (pH 5.0). 
For silanization, 400 µL of APTES was added to a final 
concentration of 5%. The mixture was incubated for 3 days 
at 60°C in sealed glass vials and vortexed from time to time. 
Unreacted APTES was removed by washing three times with 
70% ethanol. The final product was dispersed in ultrapure 
water to 0.1 µmol/µL. The presence of primary amines was 
determined by a Ninhydrin Test Kit (AnaSpec, Fremont, CA, 
USA) according to the manufacturer’s recommendations.
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NOTa and Peg conjugation to amine-
functionalized NPs
Stock solutions of the chelator p-SCN-Bn-NOTA (2 mM) 
and cross-linker MAL-PEG-SCM (20 mM) were prepared by 
diluting the compounds in DMSO and stored at -80°C until 
use. Thirty micromoles of the APTES-treated NPs was dis-
tributed in acid-washed conical tubes (1.5 mL; Thermo Fisher 
Scientific), centrifuged (16,800× g, 10 minutes), and washed 
once with 1 mL of DMSO. NPs were dispersed in 1 mL/tube 
DMSO, and p-SCN-Bn-NOTA stock solution was added to a 
molar ratio of 1.2–1 (NP to p-SCN-Bn-NOTA). To prepare 
PEGylated NPs, MAL-PEG-SCM stock solution was addi-
tionally added to a molar ratio of 1.2–1–10 (NP to SCN-Bn-
NOTA to MAL-PEG-SCM). After adjusting the pH to 8.5, 
the tubes were incubated in an Eppendorf ThermoMixer 
(Hamburg, Germany) at 37°C for 1 hour shaking (1,000 rpm) 
to prepare the final NOTA or NOTA/PEG-conjugated NPs.
64cu radiolabeling of NOTa-
functionalized NPs
To radiolabel with radioactive 64Cu, NOTA-conjugated NPs 
(both non-PEGylated and PEGylated) were washed once 
with 1 mL/tube of radiolabeling buffer (0.1 M NH
4
OAc, 
pH 5.5). After centrifugation, NPs were resuspended in 
200 µL/tube of radiolabeling buffer containing about 1 mCi 
of 64Cu (37 MBq). Radiolabeling occurred during an 1 hour 
incubation at 37°C and shaking at 800 rpm in an Eppen-
dorf ThermoMixer. To complex unreacted 64Cu, pelleted 
NPs were resuspended in 800 µL/tube PBS and 200 µL of 
chelex-treated 50 mM DTPA solution (pH 7.0) and incubated 
for further 5 minutes at 37°C (800 rpm). After washing 
once with PBS, the final products from tubes containing 
similarly treated preparations of NPs were combined in one 
tube. Centrifuged NPs were re-dispersed in sterile saline to 
obtain 10 µCi (0.37 MBq) per injection (100 µL/mouse). 
The radiochemical purity of the final products after 64Cu-
radiolabeling was analyzed by instant thin layer chroma-
tography (ITLC). Silica gel-impregnated glass fibers were 
spotted 2 cm from the bottom with 1 µL of final products. 
The plates were developed in chelex-treated 50 mM DTPA 
(pH 7.0) solution until the solvent reached 7 cm. The dried 
plates were analyzed employing a BioScan radio-TLC Imag-
ing Scanner AR-2000 (Eckert & Ziegler, Berlin, Germany) 
using the WinScan software (Version 3.13).
characterization of bare and 
functionalized NPs
The NPs were characterized by different techniques includ-
ing transmission electron microscopy (TEM), dynamic light 
scattering (DLS), laser Doppler velocimetry (LDV), and 
NP tracking analysis (NTA). TEM images were obtained 
using an FEI Tecnai G2 Spirit instrument (Thermo Fisher 
Scientific). To prepare TEM samples, 10 µL of each NP 
sample was pipetted on parafilm. Carbon-coated copper 
grids (200 mesh; TED Pella, Redding, CA, USA) were 
placed with the carbon site onto the drops and incubated 
for 1 minute. Excess samples were carefully removed with 
the outer tip of Whatman filter papers (GE Healthcare, 
Chicago, IL, USA) and grids air-dried prior to TEM imag-
ing. A Malvern Zetasizer Nano ZS (ZEN3600; Malvern 
Instruments, Malvern, UK) was used to measure particle 
sizes by DLS employing disposable polystyrene cuvettes and 
ultrapure water as diluent. To analyze the zeta potential (ZP) 
by LDV, the water-dispersed NPs were filled in disposable 
polystyrene cuvettes and measured in the Malvern Zetasizer 
Nano ZS (ZEN3600) equipped with a universal dip cell. 
Sizes of the bare particle were further determined by NTA 
in a NanoSight NS300 instrument (Malvern Instruments)
after dilution in ultrapure water and illumination by a green 
(532 nm) laser light.
cell culture
The epidermoid carcinoma cell line A431 was purchased 
from the American Type Culture Collection (ATCC) 
(Manassas, VA, USA) and cultivated in complete growth 
medium (DMEM supplemented with 10% of heat-inactivated 
FBS) in low passage number in a humidified cell incubator 
(5% CO
2
, 37°C). For xenograft mouse models, A431 
was expanded in T150 tissue culture flasks and harvested 
by trypsinization when reaching 70%–90% confluency. 
Harvested cells were washed three times with PBS and 
diluted to 5×107/mL in PBS.
Biodistribution
Animal experiments were conducted in compliance with the 
Guidelines for Care and Use of Research Animals established 
by Washington University Animal Studies Committee using 
a protocol approved by the committee. The 5–6-week-old 
female athymic nude mice (Foxn1nu/Foxn1+) were purchased 
from Envigo (Huntingdon, UK) and housed under pathogen-
free conditions in the WUSM animal facility. Mice with 
an average weight of 25 g were anesthetized by the inhala-
tion of 1%–2% isoflurane in 100% oxygen and implanted 
subcutaneously on the right shoulder with 5.0×106 A431 
cells suspended in 100 µL of PBS. Tumors were allowed to 
grow for 2 weeks reaching final tumor weights ~350 mg on 
average. In vivo biodistribution studies were conducted in 
the Washington University Small Animal Imaging Facility. 
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Isoflurane-anesthetized, tumor-bearing mice were intrave-
nously injected with about 10 µCi (0.37 MBq) of NP-NOTA-
64Cu or NP-NOTA-PEG-64Cu via the tail vein. After each 
time point (4 and 24 hours), mice were sacrificed by CO
2
 
euthanasia and cervical dislocation. Tumors and selected 
organs (blood, muscle, lung, liver, spleen, kidney, bladder, 
heart, bone, pancreas, stomach, and intestine) were col-
lected, weighted, and radioactively counted with a Beckman 
Gamma-8000 counter (Beckman Coulter, Brea, CA, USA). 
Tumor and organ uptake were analyzed and calculated as 
percentage of injected dose per gram (%ID/g).
statistics
Data are represented as the mean ± SD of at least three inde-
pendent experiments. Multiple comparisons were conducted 
by GraphPad Prism 7 (GraphPad Software, La Jolla, CA, 
USA) implementing one-way ANOVA, followed by Tukey’s 
multiple comparison test (****P,0.0001; ***P,0.001; 
**P,0.01; *P,0.05; nsP$0.05).
Results
synthesis of NPs
A novel aerosol reactor approach was developed for the 
synthesis of siliceous NPs with varying morphologies.37 The 
reactor setup (Figure S1A) and synthesis process can be 
outlined as follows. A stream of 0.9% silane gas in helium is 
further diluted with a carrier gas stream of either a helium/
nitrogen mixture (NP1) or helium (NP2 and NP3). The mixed 
gas stream then flows continuously through a thermal reactor, 
made of a stainless steel tube inside a Lindberg furnace. Inside 
the reactor, as the stream flows into hotter zones, the gas heats 
up to a critical temperature where silane starts to pyrolise and 
to undergo nucleation and condensation thus forming mono-
meric primary particles of several nanometers in diameter. 
Depending on reactor conditions and silane concentration, 
primary particles continue to grow by agglomeration to form 
larger reversible structures (agglomerates). If the residence 
time and temperature in the reactor are high enough, the 
agglomerates might coalesce to form solid irreversible NPs 
(aggregates). In general, the aerosol reactor design enabled the 
accurate control of several process parameters including tem-
perature (error proportional–integral–derivative controller: 
,±1°C), gas concentrations (error of mass flow controllers: 
,±5% of set point), and operation time. By controlling these 
parameters, specific and highly reproducible morphologies of 
synthesized SiNPs were obtained. For instance, the change 
in the reactor temperature from 600°C to 1,100°C resulted 
in an increase in the primary particle sizes and an increase in 
sphericity (Figure S1B). The geometric mean of the primary 
particle size distribution for each temperature could be repro-
duced even by different operators. For 700°C, the geometric 
mean of the primary particle size distribution was measured 
to be 10.3±0.87 nm (± standard error [SE]). At 1,000°C, the 
geometric mean of the primary particle size distribution was 
29.4±0.59 nm (± SE), while final aggregate sizes were almost 
unchanged typically with an SE of ±0.6% for the geometric 
mean of the aggregate size distribution. As a common rule, 
higher silane concentration leads to a reproducible increase in 
primary particle sizes within the investigated dynamic range 
of the reactor (ie, 25 ppm to 0.9% SiH
4
).
In this study, the reactor conditions were adjusted to synthe-
size three types of NPs with different primary particle sizes as 
summarized in Table S1. The size distributions of the produced 
NPs were monitored in real time by a scanning mobility particle 
sizer (SMPS) to guarantee reproducible size distributions inde-
pendent of the chosen conditions and run as well as to obtain 
fairly constant final aggregate sizes between all three types of 
NPs (Figure S1C). Final products were collected on quartz 
filters showing black (NP1 and NP2) to gray colors (NP3) 
(Figure S1D). To convert the Si surface to SiO
2
, products were 
treated by thermal oxidation using particle-specific conditions. 
Successful oxidation of particles was confirmed by changing 
colors of final products from black/gray (Si) to white (SiO
2
). 
The conversion of Si into SiO
2
 is expected to have occurred 
in a core–shell process, where the surface oxidizes first and 
the core of the NP at the end.38 Conversion efficacy of Si into 
SiO
2
 was calculated gravimetrically by weighing the filters 
before and after the oxidation process reaching .90% (NP2) 
or even .95% (NP1 and NP3). Control SiO
2
NPs of entirely 
spherical shape were produced by a standard sol–gel method 
as outlined in the “Materials and methods” section.
characterization of bare NPs
The morphology of final NPs was first characterized by 
TEM. The analysis of TEM pictures revealed nonspherical 
shapes for all aerosol reactor-produced NPs (NP1, NP2, 
and NP3). As a common characteristic, the NPs were built 
from smaller primary particles of fairly spherical shape 
and different sizes depending on the conditions used dur-
ing the synthesis. In contrast, the sol–gel-produced control 
particles (NP4) possessed uniform spherical shape. Figure 1 
outlines the typical morphologies of the investigated NPs 
based on their appearance in TEM using the following color 
coding throughout this publication: NP1 in green, NP2 in 
blue, NP3 in red, and NP4 in orange. To determine the size 
of the final products, DLS analysis of water-dispersed NPs 
was performed showing comparable final particle sizes 
145±33 nm (NP1: 106±17 nm, NP2: 140±11 nm, NP3: 
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146±6 nm, and NP4: 187±5 nm) (Table 1). A low polydis-
persity index (PDI) was seen for NP3 (0.10±0.01) and NP4 
(0.05±0.02), indicating narrow monodisperse distributions 
of NPs. In contrast, higher PDIs were observed for the other 
NPs suggesting moderate polydisperse distributions (NP1: 
0.49±0.05; NP2: 0.34±0.04). NPs were additionally visual-
ized by high-resolution NTA to confirm the particle sizes 
obtained by DLS. The NTA data revealed slightly larger 
Figure 1 Overview about differently shaped siliceous NPs.
Notes: representative TeM pictures (top) and the corresponding schematic sketch (bottom) of the NPs used within the study. The NPs are ordered according to their 
relative surface area from the left (NP1: highest surface area) to the right (NP4: lowest surface area). The color marking (NP1: green, NP2: blue, NP3: red, NP4: orange) is 
kept throughout the publication.
Abbreviations: NP, nanoparticle; TeM, transmission electron microscopy.
??????????????????????????????????????
??? ??? ??????
????????? ????????? ??????????????????
???
?????
???
?????
???
?????
??????????
???
Table 1 NP characterization by Dls
Sample Size ± SD  
(nm)
PDI ± SD  
(nm)
Distribution Zeta potential ± SD 
(mV)
Stability
NP1 106±17 0.49±0.05 †† -30.3±3.8 ‡‡‡‡
NP1-Nh2 400±378 0.61±0.30 ††† 14.1±0.9 ‡‡
NP1-NOTa 311±121 0.61±0.19 ††† 9.3±1.5 ‡
NP1-NOTa-Peg 395±356 0.64±0.25 ††† 0.6±0.8 ‡
NP2 140±11 0.34±0.04 †† -21.4±0.1 ‡‡‡
NP2-Nh2 339±33 0.48±0.04 †† 18.7±0.6 ‡‡
NP2-NOTa 399±56 0.38±0.05 †† 9.5±0.4 ‡
NP2-NOTa-Peg 1,079±573 0.36±0.23 †† 5.4±0.1 ‡
NP3 146±6 0.10±0.01 † -25.6±1.1 ‡‡‡
NP3-Nh2 427±74 0.18±0.01 †† 20.5±0.4 ‡‡‡
NP3-NOTa 426±33 0.24±0.01 †† 10.3±0.4 ‡‡
NP3-NOTa-Peg 801±452 0.41±0.11 †† -12.3±3.7 ‡‡
NP4 187±5 0.05±0.02 † -40.9±0.4 ‡‡‡‡
NP4-Nh2 396±75 0.57±0.28 ††† 4.9±0.3 ‡
NP4-NOTa 448±213 0.55±0.21 ††† -13.4±1.6 ‡‡
NP4-NOTa-Peg 244±74 0.86±0.25 ††† -2.4±0.3 ‡
Notes: Types of distribution in DLS measurements were defined as follows: † 0.0–0.1, narrow monodisperse; †† 0.1–0.5, moderate polydisperse; ††† .0.5, broad 
polydisperse. The colloid stability in LDV analysis was defined as described below: ‡ ±0–10, highly unstable; ‡‡ ±10–20, relatively stable; ‡‡‡ ±20–30, moderately stable; 
‡‡‡‡ .±30, highly stable. averages were calculated from at least three (n=3) independent measurements. green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: Dls, dynamic light scattering; lDV, laser Doppler velocimetry; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; PDI, polydispersity 
index; Peg, polyethylene glycol.
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sizes of NPs with on average 174±18 nm. Sizes of NPs with 
low PDI in DLS measurements were almost identical in 
NTA (NP3: 148±77 nm; NP4: 188±46 nm). However, NPs 
with higher PDIs in DLS showed increased particle sizes in 
NTA, ie, NP1 (184±76 nm) and NP2 (175±65 nm). To gain 
further information about the particle morphology, TEM pic-
tures were analyzed by ImageJ (National Institute of Health, 
Bethesda, MD, USA) to determine the average sizes of the 
single spherical subunits. By measuring the spherical areas 
(n=100), diameters of primary particles were calculated. 
NP1 showed the smallest subunit sizes with only 6±2 nm in 
diameter, followed by NP2 with 14±3 nm and finally NP3 
with an average diameter of 41±11 nm (Figure S2). Due to 
the monodisperse nature of the spherical control particles, 
the ImageJ analysis was used to additionally confirm the 
final particles sizes of NP4 with 187±39 nm. Based on 
the appearance in TEM and the similar final particle sizes, 
the relative surface areas of final particles were estimated 
assuming a spherical composition of all final products. The 
smallest surface area was anticipated for the entirely spherical 
control particle NP4 and increased for the nonspherical NPs 
depending on the sizes of their primary subunits from large 
for NP3 (41 nm), via intermediate for NP2 (14 nm), to small 
for NP1 (6 nm) (Figure 1).
Functionalization and characterization 
of modified NPs
In preparation for 64Cu radiolabeling and in vivo tracking 
in tumor-bearing mice, NPs were modified by various com-
pounds, including APTES, NOTA, and PEG. First, bare NPs 
were chemically treated with APTES to cover the surfaces 
with organofunctional alkoxysilane molecules. Silanization 
was performed for up to 72 hours at 60°C using 5% APTES 
dissolved in an ethanol/water mixture. Successful functionaliza-
tion of the various NPs was confirmed by a semiquantitative 
ninhydrin test kit (data not shown). In the next step, the silanized 
NPs were conjugated to the NOTA chelator using the amine-
reactive cross-linker p-SCN-Bn-NOTA. Primary amines of 
silanized NPs were reacted with the isothiocyanate groups of 
p-SCN-Bn-NOTA to form stable thiourea bonds in DMSO at 
pH 8.5 for 1 hour at 37°C as described. To further investigate 
the influence of PEGylation on biodistribution of the NPs, 
amine-reactive MAL-PEG-SCM was optionally added during 
the chelator reaction using a molar excess of MAL-PEG-SCM 
to SCN-Bn-NOTA of 10–1. Primary amines of silanized NPs 
reacted with the succinimidyl NHS ester group of MAL-PEG-
SCM to stable carboxamide bonds, thus adding an additional 
5 kDa linear PEG chain to the functionalized NPs.
The NPs were then characterized by DLS in order to 
determine potential changes in particle sizes. The data for the 
DLS measurements of water-dispersed NPs are summarized 
in Table 1. On average, silanization of bare NPs by APTES 
lead to about a threefold increase in particle size, independent 
of the particle shape. NOTA conjugation to silanized NPs did 
not change the size further. An approximate 1.7-fold increase 
in particle size was observed when PEG was used. The PDI 
for the DLS measurements was in the moderate polydisperse 
range (0.1–0.5) for all functionalized samples of NP2 and 
NP3. In contrast, broad polydispersity (.0.5) was observed 
for NP1 and NP4 after all functionalization steps.
To investigate the influence of the surface modification 
on stability, the ZPs of water-dispersed NPs were evaluated 
(Table 1). As described below, the different functionalization 
steps changed the ZPs of the NPs in similar ways indepen-
dent of the particle type. In general, the bare particles gave 
negative ZPs with an average of -30±8 mV, indicating 
moderate (NP2 and NP3) to high (NP1 and NP4) stabilities. 
Compared to these bare particles, surface modification by 
APTES treatment increased (44±3 mV) the ZPs to 15±7 mV 
suggesting reduced stabilities (relatively stable: NP1 and 
NP2; moderately stable: NP3; and highly unstable: NP4). 
The further addition of chelator NOTA to the silanized NPs 
decreased (-11±6 mV) the ZPs to an average of 4±12 mV, 
signaling even lower overall stabilities (relatively stable: 
NP3 and NP4; highly unstable: NP1 and NP2). Similar to the 
NOTA conjugation alone, the addition of both NOTA and 
PEG to the silanized NPs resulted in a comparable decline 
(-17±11 mV) of the ZPs close to zero (-2±8 mV), indicat-
ing again very low colloid stabilities (relatively stable: NP3; 
highly unstable: NP1, NP2, and NP4).
radiolabeling and biodistribution of NPs
As a final step, in vivo mouse studies were conducted in order 
to determine the impact of the NP shape and PEGylation on 
organ distribution and tumor uptake. Therefore, the various 
types of NOTA-conjugated NPs were first radiolabeled with 
64Cu. To guarantee high radiochemical purity of the final 
products before injection, ITLC of the 64Cu-radiolabeled 
NPs was performed. The ITLC profiles confirmed the high 
efficacy of radiolabeling with an average radiochemical 
purity of 93%±12% as calculated from the regions of interests 
(ROIs). For proper comparison, 10 µCi (0.37 MBq) of the 
final radiolabeled NPs were injected in the tail vein in athy-
mic nude mice bearing A431-tumor xenografts. Mice were 
sacrificed after 4 or 24 hours to determine the uptake of the 
radioactive NPs as %ID/g into selected organs and tumors. 
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The complete dataset of this biodistribution study is given in 
Tables S2–S5, including all collected organs and the tumors. 
Based on the distinct nature of the NPs, significant differ-
ences in the uptake profiles of the particles were observed. 
In general, the highest uptake of radiolabeled NPs was seen 
for lung, liver, spleen, kidneys, and intestine. In contrast, 
tumors and all other investigated organs showed lower 
overall uptake of radiolabeled NPs. To better emphasize 
these differences, only the biodistribution data of relevant 
organs and tumors are discussed separately and, in more 
detail, below. The biodistribution of non-PEGylated NPs 
in the major organs is shown in Figure 2A (4 hours) and 
Figure 2B (24 hours), and that of PEGylated NPs is shown 
in Figure 3A (4 hours) and Figure 3B (24 hours). Due to the 
scale difference, the uptake in the tumors after 24 hours is 
shown separately (Figure 4).
lung uptake
The apparent uptakes of radiolabeled NPs into the 
lungs showed dramatic differences between various 
types of NPs. Very high initial lung uptake (non-PEG: 
108.84±19.07%ID/g; PEG: 126.06±14.51%ID/g) was 
observed for aerosol-synthesized NP1 possessing the highest 
relative surface areas of all particles. In contrast to all other 
types of NPs (all ,37.46%ID/g), the lung uptake of NP1 at 
the 4 hours time point was significantly increased for both 
non-PEGylated and PEGylated NPs (all P,0.0001). Inter-
estingly, this high uptake of NP1 into the lungs was mostly 
dependent on the circulation time but not on the PEGylation 
status. The uptake in lungs clearly decreased after 24 hours 
(non-PEG: 12.86±3.37%ID/g; PEG: 20.23±5.72%ID/g), 
showing less significant differences compared to the other 
NPs. Moreover, the calculated P-values of the non-PEGy-
lated and PEGylated products confirmed that the lung uptake 
of NP1 was independent of PEGylation (4 hours: P=0.2484; 
24 hours: P=0.4278). According to this, PEGylation had no 
significant effect on lung uptakes for the other NPs (4 hours: 
all P.0.1128; 24 hours: all P.0.9999).
In summary, aerosol-synthesized NP1 with the highest 
surface area of all particles showed superior lung uptake after 
4 hours. This effect was almost negated after 24 hours when 
compared with the other NPs. PEGylation had no significant 
influence on lung uptake for any particle type.
liver uptake
By analyzing the liver distributions, very significant dif-
ferences were calculated for the aerosol-synthesized NP2 
after PEGylation compared to all other NPs (all P,0.0007). 
NP2 showed the highest liver uptake after PEGylation of 
all NPs that was independent of the analyzed time point 
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Figure 2 Biodistribution of NP-NOTa-64cu in tumor-xenografted mice.
Notes: athymic nude mice bearing a431 tumors were injected intravenously with 10 µCi of single conjugate. Mice were sacrificed after 4 hours (A) or 24 hours (B). Tumors 
and selected organs were harvested, weighted, and analyzed by γ-counting to determine %ID/g. Data are expressed as mean ± sD %ID/g based on n=4 animals per group. 
statistical analysis was performed by one-way aNOVa, followed by Tukey’s multiple comparison test (****P,0.0001; ***P,0.001; **P,0.01; *P,0.05). green: NP1-NOTa-
64cu, blue: NP2-NOTa-64cu, red: NP3-NOTa-64cu, and orange: NP4-NOTa-64cu.
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle.
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Figure 3 Biodistribution of Pegylated NP-NOTa-64cu in tumor-xenografted mice.
Notes: athymic nude mice bearing a431 tumors were injected intravenously with 10 µCi of single conjugate. Mice were scarified after 4 hours (A) or 24 hours (B). Tumors 
and selected organs were harvested, weighted, and analyzed by γ-counting to determine %ID/g. Data are expressed as mean ± sD %ID/g based on n=4 animals per group. 
statistical analysis was performed by one-way aNOVa, followed by Tukey’s multiple comparison test (****P,0.0001; ***P,0.001; **P,0.01; *P,0.05). green: NP1-NOTa-
Peg-64cu, blue: NP2-NOTa-Peg-64cu, red: NP3-NOTa-Peg-64cu, orange: NP4-NOTa-Peg-64cu.
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; Peg, polyethylene 
glycol.
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Figure 4 Tumor uptake of radiolabeled NPs in tumor-xenografted mice.
Notes: Tumor uptake was calculated based on the biodistribution data for non-
Pegylated (left) and Pegylated (right) NP-NOTa-64cu after 24 hours of circulation. 
Data are expressed as mean ± sD %ID/g based on n=4 animals per group. statistical 
analysis was performed by one-way aNOVa, followed by Tukey’s multiple 
comparison test (****P,0.0001; **P,0.01; *P,0.05). green: NP1, blue: NP2, red: 
NP3, orange: NP4.
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; 
NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; Peg, 
polyethylene glycol.
(4 hours: 64.54±4.07%ID/g; 24 hours: 55.77±8.33%ID/g). 
Furthermore, the high liver uptake of NP2 was unaffected by 
PEGylation (4 hours: P=0.8864; 24 hours: P=0.9943), reach-
ing similar high overall uptakes for the non-PEGylated NP2 
(4 hours: 57.28±4.24%ID/g; 24 hours: 52.95±2.68%ID/g). 
Similarly, the intermediate liver uptake of spherical NP4 
(4 hours: 34.17±14.35%ID/g; 24 hours: 26.02±4.96%ID/g) 
did not significantly change after PEGylation (4 hours: 
P=0.6345; 24 hours: P=0.1742). The other nonspheri-
cal particle NP1 (4 hours: 39.64±4.56%ID/g; 24 hours: 
31.11±5.72%ID/g) and NP3 (4 hours: 63.06±13.29%ID/g; 
24 hours: 44.74±4.04%ID/g) revealed higher relative accu-
mulation in that organ. However and in contrast to NP2 and 
NP4, PEGylation led to a significant drop in liver uptake of 
both NP1 (4 hours: P=0.0003; 24 hours: P,0.0001) and NP3 
(4 hours: P=0.0014; 24 hours: P=0.0015).
Overall, the aerosol-synthesized NP2 showed relatively 
high uptake into the liver that was time and PEGylation 
independent. Similar to this, the intermediate liver uptake 
of sol–gel-synthesized NP4 was PEGylation independent. 
In contrast, the intermediate (NP1) or high (NP3) liver 
uptake of the remaining aerosol-synthesized NPs was clearly 
decreased when PEGylated.
spleen uptake
The analysis of spleen uptakes showed an extremely high 
accumulation of non-PEGylated NP3 (nonspherical, low 
surface area) after 4 hours (117.97±6.57%ID/g) that was 
significantly higher than for all other NPs (all P,0.0003). 
This effect of increased spleen uptake of NP3 was mostly 
dependent on time and PEGylation status showing lower 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
25
2.
17
4.
22
0 
on
 2
9-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7384
Diebolder et al
uptake after 24 hours (63.01±23.13%ID/g) or PEGylation 
(4 hours: 46.71±21.08%ID/g; 24 hours: 27.45±6.66%ID/g). 
Calculating the P-values confirmed that the observed dif-
ferences between non-PEGylated and PEGylated NP3 
were significant (4 hours: P,0.0001; 24 hours: P=0.0237). 
NP1 revealed intermediate (4 hours: 44.95±12.46%ID/g) 
or low (24 hours: 26.66±4.04%ID/g) spleen uptake that 
decreased after PEGylation (4 hours: 4.89±1.02%ID/g, 
P=0.0106; 24 hours: 4.11±0.58%ID/g, P=0.3267). High 
apparent uptake (4 hours: 63.45±24.78%ID/g; 24 hours: 
77.02±18.71%ID/g) was seen for the NP2 independent 
of PEGylation (4 hours: P=0.9294; 24 hours: P=0.3702). 
The spherical control NP4 showed only low spleen uptake 
(4 hours: 16.15±7.95%ID/g; 24 hours: 9.13±1.60%ID/g) 
also independent of PEGylation (4 hours: P=0.9987; 
24 hours: P.0.9999).
In summary, very high initial spleen uptake was 
observed for non-PEGylated NP3 that decreased over time. 
PEGylation reduced the spleen uptake of NP3 dramatically. 
A similar behavior (ie, higher initial spleen uptake when 
non-PEGylated) was observed for NP1, although the overall 
uptake was clearly lower. In contrast, overall high or low 
spleen uptake was observed for NP2 and NP4, respectively, 
but independent of time and PEGylation.
Kidney uptake
Uptake of NPs in the kidneys was lower when compared 
with the lung, liver, and spleen. Interestingly, the kidney 
uptake seemed to be mainly time independent for all 
types of NPs. The highest accumulation was seen for the 
spherical NP4 (4 hours: 10.59±3.37%ID/g; 24 hours: 
12.97±4.78%ID/g), followed by the nonspherical NP3 
(4 hours: 8.68±1.32%ID/g; 24 hours: 8.28±0.97%ID/g), NP1 
(4 hours: 4.13±0.57%ID/g; 24 hours: 4.08±0.47%ID/g), and 
finally NP2 with very low overall kidney uptake (4 hours: 
0.62±0.06%ID/g; 24 hours: 0.60±0.07%ID/g). PEGylation 
of the nonspherical NPs had no major impact on the kidney 
uptake (all P.0.1971). However, PEGylation of the spherical 
NP4 was more relevant especially after 24 hours (4 hours: 
P=0.0904; 24 hours: P=0.0029), showing an overall reduced 
kidney accumulation (4 hours: 7.26±2.09%ID/g; 24 hours: 
7.11±0.72%ID/g).
The kidney uptake was higher for the spherical NP4 
than for all nonspherical NPs. Almost no differences 
between the time points in kidney uptake could be mea-
sured. PEGylation had no significant influence on kidney 
uptake for the nonspherical NPs and moderate effect on 
the spherical NP4 after 24 hours with a slightly decreased 
kidney uptake.
Intestinal uptake
Highest intestinal uptake was observed for nonspherical NP3 
(4 hours: 23.96±2.90%ID/g; 24 hours: 17.05±1.97%ID/g), 
followed by spherical NP4 (4 hours: 16.92±6.74%ID/g; 
24 hours: 13.12±2.02%ID/g), and nonspherical NP1 (4 hours: 
12.43±1.21%ID/g; 24 hours: 8.10±1.01%ID/g). As already 
seen for the kidneys, the accumulation of NP2 into the intes-
tine was very limited (4 hours: 1.36±0.04%ID/g; 24 hours: 
0.82±0.08%ID/g) and significantly lower than for all other 
NPs. Independent of the particle morphology, the differ-
ences of intestinal uptake to the two different time points 
were mostly not significant (all P.0.4076) except for NP3 
with a slight significant decrease over time (P=0.0372). 
PEGylation did not change intestinal uptake for NP1, NP2, 
and NP4 (4 hours: P all .0.7973; 24 hours: P all .0.2321). 
However, a significant decrease in intestinal uptake was 
observed after PEGylation of NP3 (4 hours: P,0.0001; 
24 hours: P=0.0002).
In summary, there was a significantly higher intestinal 
uptake of NP3 than for all other NPs, especially to the early 
time point. In contrast to all other particles, there was a 
significant decrease in the intestinal uptake of NP3 after 
PEGylation, especially after 4 hours.
Tumor uptake
Good tumor penetration and retention are essential for the 
successful development of NPs as potential vectors for 
delivering therapeutic payloads and for imaging cancer. 
Figure 4 compares the tumor uptakes for the non-PEGylated 
vs PEGylated NPs after 24 hours. In general, the uptake of 
NPs into the A431 tumors showed a pattern similar to that 
observed for the kidneys. The highest uptake in tumors was 
seen for the spherical NP4 (non-PEG: 5.39±1.31%ID/g; 
PEG: 5.05±1.30%ID/g), followed by the nonspherical NP3 
(non-PEG: 3.61±1.02%ID/g; PEG: 2.70±0.67%ID/g), 
NP1 (non-PEG: 1.38±0.10%ID/g; PEG: 0.84±0.33%ID/g), 
and NP2 with very low overall tumor uptake (non-PEG: 
0.11±0.01%ID/g; PEG: 0.15±0.05%ID/g). By analyzing 
the P-values, this pattern was basically independent of time 
(NOTA: all P.0.2663; PEG: all P.0.5292) or PEGylation 
(4 hours: all P.0.9765; 24 hours: all P.0.7299).
Overall tumor uptake was higher for spherical NP4 
than for the nonspherical NPs (NP3.NP1.NP2). In gen-
eral, tumor uptakes were basically independent of time or 
PEGylation.
Tumor-to-organ ratios
Based on the uptakes obtained during the in vivo mice 
studies, both tumor-to-blood (TTB) and tumor-to-muscle 
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(TTM) ratios were calculated (Table S6), showing non-
significant differences between both time points (all 
P.0.0883). Figure 5A highlights the calculated TTB and 
Figure 5B the TTM ratios after 24 hours. Analogous to the 
absolute tumor uptakes, the highest ratios were observed 
for the spherical NP4 (TTB: 3.13±0.62; TTM: 7.76±0.31) 
that was significantly higher than for all the nonspherical 
NPs. No significant differences were seen between various 
nonspherical NPs neither in TTB (NP1: 1.66±0.31, NP2: 
1.38±0.19, and NP3: 1.58±0.50) nor in TTM ratios (NP1: 
4.12±1.14, NP2: 4.39±1.36, and NP3: 4.34±1.12). By ana-
lyzing the P-values, PEGylation of NPs had no significant 
influence on neither the TTB ratio (all P.0.5984) nor the 
TTM ratio (all P.0.9891).
In summary, sol–gel-produced NP4 showed higher TTB 
and TTM ratios than the aerosol-synthesized NPs. In fact, 
no significant difference in ratios of TTB and TTM could 
be measured between the aerosol-synthesized NPs. Both 
TTB and TTM ratios were independent of the time point and 
PEGylation for all investigated NPs.
Discussion
Particle synthesis
In this study, we implemented an aerosol reactor approach to 
synthesize morphologically different siliceous NPs of similar 
aggregate sizes (~170 nm) for their evaluation in biomedical 
applications. Based on the process, these compounds are 
composed of primary spherical subunits of different sizes (ie, 
6, 14, and 41 nm) but form stable aggregates due to thermal-
induced sintering during particle synthesis. Most current 
technologies for the production of biomedical siliceous NPs 
often rely on liquid phase techniques (ie, sol–gel methods 
for the synthesis of SiO
2
NPs)27,39 or top-down approaches 
(ie, etching and milling for the fabrication of pSi).19,40 In 
contrast, the de novo growing in the gas phase is mainly used 
to synthesize smaller (,10 nm) colloidal SiNPs for imaging 
applications (eg, Si QDs).33 Here, different technologies 
have been established including supersaturated Si vapor 
in a microplasma reactor41 or by the pyrolysis of silane gas 
in a microwave plasma reactor.42 Last but not least, fumed 
silica may be synthesized by high temperature hydrolysis of 
SiCl
4
 in an O
2
(N
2
)/H
2
 flame, where small primary SiO
2
NPs 
(5–50 nm) form branched hard-agglomerates but usually 
grow up to micrometer size (0.1–100 µm) and are mainly 
used in industrial applications.43 In our approach, we used a 
furnace aerosol reactor for the pyrolysis (ie, thermal anoxic 
decomposition) of monosilane (SiH
4
) gas to grow SiNPs of 
defined nanometer size and morphologies, which might also 
be valuable for biomedical applications. Historically, early 
attempts in the aerosol-assisted production of NPs were often 
developed empirically since a theoretical understanding of 
the physico-chemical details was missing. Indeed, aerosol 
Figure 5 Tumor-to-organ ratios of radiolabeled NPs in tumor-xenografted mice.
Notes: Tumor-to-blood (A) or tumor-to-muscle (B) ratios were calculated based on the biodistribution data for non-Pegylated (left) and Pegylated (right) NP-NOTa-
64cu after 24 hours of circulation. ratios were calculated separately for each mouse based on the %ID/g data and expressed as mean ± sD involving n=4 mice per group. 
statistical analysis was performed by one-way aNOVa, followed by Tukey’s multiple comparison test (****P,0.0001; ***P,0.001; **P,0.01). green: NP1, blue: NP2, red: 
NP3, orange: NP4.
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; Peg, polyethylene glycol.
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synthesis of SiNPs is composed of several overlapping steps 
(chemical reaction, nucleation, growth, agglomeration, and 
under some circumstances, sintering) that are challenging 
to study due to the high temperatures, short reaction times, 
and limited access to track the reaction.44 Nevertheless, 
recent improvements in multiscale modeling of the aerosol 
synthesis process for SiNPs have allowed better predic-
tions in the synthesis of narrow sized primary particles and 
controlling the synthesis process.44 In accordance, we have 
developed a reactor setup and process control that allowed 
us to produce narrow size distributions of primary SiNPs that 
differed depending on the reactor temperature. Yet, the final 
size distributions of sintered aggregates remained practically 
unaffected during synthesis within a broad temperature range 
of 600 to 1,100°C. Based on this observation, we developed 
a stable process to synthesize aggregates of similar size dis-
tributions but made of primary particles of different sizes to 
analyze their potential in biomedical applications.
Particle functionalization
Several approaches are now available to study the biodistri-
bution of NPs, including inductively coupled plasma-optical 
emission spectroscopy/mass spectrometry, fluorescence, and 
radiolabeling. Based on our long-standing expertise, we per-
formed radiolabeling with 64Cu to evaluate the potential of our 
aerosol-synthesized NPs for bio-applications. This technique 
requires the covalent linkage of copper chelators (eg, NOTA) 
to the particle surface. In general, surface modification of 
the SiNPs (eg, colloid Si QDs) can be achieved by various 
techniques to generate either hydride or halogen-terminated 
surfaces. In a next ligand exchange step, hydrosilylation of 
the hydride-terminated or nucleophilic substitution of the 
halogen-terminated surfaces is performed to establish robust 
covalent linkages between the Si surface atoms and carbon, 
nitrogen, or oxygen species.32 These techniques allow the 
formation of self-assembled monolayers (SAMs) of a variety 
of distal moieties and are highly useful for subsequent func-
tionalization steps. In contrast to these mentioned approaches, 
we decided on another widely used strategy of Si surface 
modification by adding stable silica shells to the Si cores. 
Here, thermal oxidation is by far the most used process due to 
its simplicity, adaptability, and relatively low cost of imple-
mentation. Thermal oxidation of our aerosol-synthesized Si 
particles was performed under morphology-dependent condi-
tions and required high temperatures with varying exposure 
times of up to several hours. In general, successful oxidation 
of SiNPs can be performed in a wide range of process tem-
peratures (RT to 1,100°C) that requires very little oxygen.45 
Thermal oxidation of SiNPs occurs in a two-step shrinking 
core model46 and might result in stable silica layers of different 
oxygen contents and sometimes different surface hydride spe-
cies depending on the condition used for thermal treatment.38 
Since all our particles have been processed at a temperature 
of $500°C, it can be anticipated that these particles contain 
a crystalline Si core, covered by a layer of amorphous Si and 
an outer Si oxide shell highly valuable for further particle 
functionalization. Moreover, we preferred the silica conver-
sion strategy for the following two additional reasons: first, 
SiO
2
NPs possess prolonged circulation times and in vivo 
stabilities compared to their Si counterparts (half-life of days 
compared to hours). Second, there are a variety of well-known 
silica surface modification technologies on hand including 
those based on various commercially available alkoxysilanes 
and halosilanes.47 In the case of alkoxysilanes, stable 1–3 
Si-O-Si links with the surface silanol groups (≡Si-OH) are 
formed in a condensation reaction. Most frequently, APTES 
or (3-mercaptopropyl)-trimethoxysilane (MPTMS) is used for 
silica surface modification to add either aminopropyl silane 
(APS) or mercaptopropyl silane (MPS) films. The covalently 
linked primary amines (-NH
2
) or thiol groups (-SH) of such 
modified silica surfaces facilitate the linker chemistry with 
other frequently used linking moieties including those based 
on n-hydroxysuccinimide (NHS), isothiocyanates (both for 
amine coupling), or maleimides (for thiol coupling). In the 
current study, the silica surface of our NPs was modified 
with primary amines by APTES treatment to allow subse-
quent functionalization with NHS-functionalized NOTA or 
NHS-functionalized PEG. However, APTES treatment has 
increased the apparent sizes of our aerosol-synthesized NPs 
by about threefold. Since this effect was also observed for 
our spherical control particles, we conclude that the particle 
aggregation after amine modification was independent of the 
morphology. The phenomena of aggregation of SiO
2
NPs after 
APTES treatment can be explained by an excess of positively 
charged amino groups on the silica surface at physiological 
pH.48 Indeed, APTES treatment of our NPs increased the 
ZPs by an average of 44.1±2.8 mV to the low positive range 
indicating decreased overall particle stabilities. APTES-
modified SiO
2
NPs are known to back-bond primary amines to 
surface silanol groups that might induce particle aggregation 
due to the reduced shear plane and electrostatic repulsion. 
Subsequent functionalization by NOTA or NOTA/PEG 
moieties slightly decreased ZPs but still stayed in the range 
of low overall stability (ie, around ±0 mV). Thus, decreasing 
the ratio of surface amines to silanol groups should reduce 
particle aggregation and improve biocompatibility. Although 
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not performed here, quantitative methods to determine the 
number of functional amine groups were reported49 and could 
help to optimize the condition for surface modification and 
to further increase the particle dispersibility. Alternatively, 
adding other inert functional groups and/or negatively 
charged moieties (eg, methylphosphonate) can increase the 
overall solubility by preventing back-bonding48 and might 
be a valuable strategy to improve the biocompatibility of our 
aerosol-synthesized NPs.
Biodistribution
Silica offers several advantages for biomedical research 
compared to other nanomaterials but often suffer from poor 
biodistribution with high uptake by the cells of the reticuloen-
dothelial system (RES).20 In terms of passive targeting of solid 
tumors, best hydrodynamic stability in the bloodstream of 
SiO
2
NPs is achieved by keeping the particle size between 50 
and 300 nm, since particles above 300 nm usually tend to get 
recognized by the RES whereas smaller particles (,50 nm) 
might nonspecifically distribute in the body.50 More recent 
preclinical data suggest that the highest EPR effect in target 
tissue can be obtained for NPs with rigid core size between 
100 and 220 nm while emphasizing the importance of the 
particle surface charge on biodistribution.51 In this regard, 
high negative ZPs might improve both stabilities and the EPR 
effect, whereas high positive ZPs increase either cytotoxic-
ity (smaller NPs) or recognition by the RES (NPs .150 nm 
core size). Based on this knowledge, we implemented the 
aerosol reactor technology to generate siliceous NPs with a 
final rigid core size of on average ~170 nm and high nega-
tive ZP (about -30 mV) to increase the EPR effect in our 
tumor model. However, the DLS data suggest that surface 
modification (ie, APTES, NOTA, and PEG) increased the 
hydrodynamic sizes independent of the particle morphol-
ogy (.300 nm) that might have reduced tumor penetration 
and facilitated RES recognition. The mouse biodistribu-
tion studies revealed that the majority of our radiolabeled 
SiO
2
NPs (up to 126%ID/g) accumulated in the organs of the 
RES (ie, liver, spleen, and lung), followed by intermediate 
uptake (up to 24%ID/g) in the intestine and kidney (Figures 2 
and 3). In contrast, the particle accumulation in the other 
organs (Tables S2–S5) including blood, muscle, and human 
A431 xenografts (Figure 4) was rather low (,6%ID/g). 
Despite this general pattern of organ distribution, the rela-
tive organ uptakes of the SiO
2
NPs varied dependently on the 
particle morphology. For instance, aerosol-synthesized NP1 
composed of small primary particles highly accumulated in 
lungs at the early time point (109%ID/g) but dramatically 
decreased after only 24 hours (lung uptake NP1: ,13%ID/g), 
an effect that was much stronger than for any of the other 
investigated NPs. Initially increased lung concentrations 
of SiO
2
NPs that decreased over time have been described 
previously and were suggested to be caused by the uptake 
and migration of alveolar phagocytes.52 We conclude that the 
unique morphology with high surface area of NP1 increased 
the uptake by alveolar phagocytes, although an initial block-
age of small lung capillaries by NP1 might have contributed 
to this effect as well. Similarly, the unique morphology of 
aerosol-synthesized NP3 resulted in strong initial spleen 
uptake (4 hours: 118%ID/g vs 24 hours: 63%ID/g) that 
was likely caused by the preferred uptake of NP3 through 
spleen macrophages. Nevertheless, our 24 hour biodistribu-
tion data suggest that the majority of injected particles accu-
mulated in the liver independent of the particle morphology. 
Being the largest organ of the mouse body (around 1 g), 
calculation of the organ uptake (%ID/organ) indeed revealed 
high liver accumulation for all particles (NP1: 34%, NP2: 
61%, NP3 48%, and NP4: 25%). This is in accordance with 
other reports indicating that the liver usually sequesters the 
majority (up to 99%) of administered NPs from the blood-
stream and typically less than 5% of the injected NPs are 
delivered to the diseased tissue.53 As a matter of fact, tumor 
uptakes were highly dependent on the particle morphology. 
Here, aerosol-synthesized NPs with large primary subunits 
and smaller overall surface area (NP3) showed superior 
tumor penetration and retention compared to those made of 
smaller primary subunits (ie, NP1 and NP2). Interestingly, 
PEGylation of our aerosol-synthesized NPs showed minor 
effects on blood circulation and uptake by tumors. This is 
in contrast to many studies, although there are some studies 
that have demonstrated that PEGylation can have a minimal 
effect on tumor uptake.54,55 Nevertheless, we did observe 
some differences between PEGylated and non-PEGylated 
NPs in organs of the RES (eg, reduced liver and spleen 
uptake by NP1 and NP3). The DLS data suggest that PEGyla-
tion might have impaired efficient tumor penetration of the 
aerosol-synthesized NPs due to an increase in hydrodynamic 
radius above the critical cutoff size for efficient microvascular 
permeability (ie, 400–600 nm for most tumors).56 In fact, 
our aerosol-synthesized NPs, in general, showed a higher 
susceptibility for aggregation after PEGylation than the 
spherical NP4 possessing the highest tumor uptake, TTB, and 
TTM ratios of all particles. In general, nonspecific uptake 
of SiO
2
NPs through the RES does not lead to any long-term 
toxicity since decomposition and clearance of SiO
2
NPs, 
though biliary (ie, feces) and renal system (ie, urine) usually 
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occurs within a few weeks.22 We believe that our SiO
2
NPs 
would have a similar low toxicity; however, this will need 
to be confirmed in future studies. Nevertheless, drug-loaded 
therapeutic NPs might result in systemic toxicity if nonspe-
cifically unloaded in nontarget tissue. In this regard, further 
fine-tuning of our functionalization procedure is warranted 
to reduce the particle aggregation and RES uptake.
Conclusion
The goal of this study was to evaluate the general biodis-
tribution of siliceous NPs that were synthesized by a novel 
aerosol reactor-based approach and to further demonstrate 
the feasibility of this technology to generate biodegradable 
NPs with biomedical potential. In vivo biodistribution of 
the 64Cu-radiolabeled NPs revealed predominant uptake by 
the phagocytic cells of the RES in liver (Kupffer cells), spleen 
(red pulp macrophages), and lung (alveolar macrophages). 
The significant differences of the aerosol-synthesized NPs in 
organ distribution were mainly caused by the different mor-
phologies of the investigated particles, although the change 
of other physiochemical characteristics (eg, hydrodynamic 
size and ZP) might have contributed to this effect as well. 
In terms of the highest tumor uptake and retention, aerosol-
synthesized NPs composed of large primary subunits and 
smaller overall surface area (NP3) seemed to be superior 
over those composed of smaller subunits (NP1 and NP2), 
suggesting the potential of NP3 in the development as a tumor 
imaging or therapeutic agent. Although similar technologies 
for the synthesis of siliceous particles by aerosol reactors 
have been reported previously, this study represents, to our 
knowledge, the first investigation regarding the potential of 
such synthesized NPs for biomedical applications. Never-
theless, we observed a high uptake of our NPs by the RES 
that is in accordance with many other in vivo reports about 
siliceous NPs for biomedicine. In this regard, further optimi-
zation of the synthesis and functionalization process of our 
aerosol-derived NPs seems to be warranted to improve tumor 
penetration and retention in upcoming studies. In terms of 
synthesis, adjusting the reactor conditions to produce larger 
primary subunits of sintered or even spherical nonsintered 
particles might be favorable. Last but not least, incorporation 
of functional groups (eg, organosilica) during the aerosol 
synthesis process to produce organosilica or silsesquioxane 
NPs might further expand the potential of this technology 
in terms of biomedical usage. Overall, the current data 
suggest that the silane aerosol reactor approach is valuable 
in generating sintered siliceous aggregates on a nanoscale 
that are safe and promising for use in future imaging and/or 
therapeutic applications.
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Figure S1 silane aerosol reactor for the production of siliceous NPs.
Notes: (A) The setup of the aerosol reactor allowing the controlled synthesis of nonspherical siNPs by the pyrolysis of silane gas in a lindberg furnace. The rector 
temperature had a major impact on the primary particle size of formed siNPs (B). The smallest primary particles were seen at 600°c steadily growing in size up to about 
900°c. above this temperature, primary particle sizes only slightly decreased but formed highly spherical primary particle shapes. reactor conditions were chosen to produce 
three types of NPs (NP1, NP2, and NP3) with similar final aggregate size distribution as live-monitored by a SMPS (C). SiNPs were finally converted into SiO2 by thermal 
oxidation as obvious by change in color from gray/black to white (D).
Abbreviations: NP, nanoparticle; sMPs, scanning mobility particle sizer.
Table S1 reactor conditions and parameters
Sample Reactor  
temperature (°C)
Silane  
concentration (%)
Reactor operation  
time (hours)
Residence  
time (s)
Relative primary 
particle size
NP1 1,000 0.004 10 0.28±0.03 small
NP2 600 0.02 10 2.14±0.13 Intermediate
NP3 1,000 0.02 10 1.47±0.09 large
Notes: green: NP1, blue: NP2, red: NP3. 
Abbreviation: NP, nanoparticle.
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Figure S2 Primary particle sizes of NPs by TeM analysis.
Notes: Primary subunits of the aerosol reactor produced nonspherical NP1 (A), NP2 (B), NP3 (C), and the sol–gel-produced spherical NP4 (D) were analyzed by ImageJ 
employing TEM pictures of the final products. In case of the nonspherical NPs, frequency distributions are based on area measurements of randomly chosen primary subunits 
assuming spherical subunits for calculating particle diameters. In case of NP4, the areas of the single monodisperse spheres were measured to confirm the final particle sizes. 
histograms were created by graphPad Prism implicating a gaussian distribution. sizes were calculated as mean ± sD based on 100 independent measurements.
Abbreviations: NP, nanoparticle; TeM, transmission electron microscope.
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Table S2 Biodistribution of NP-NOTa-64cu in a431 tumor-xenografted mice after 4 hours
Organ NP1-NOTA-64Cu NP2-NOTA-64Cu NP3-NOTA-64Cu NP4-NOTA-64Cu
%ID/g ± SD %ID/g ± SD %ID/g ± SD %ID/g ± SD
Tumor 1.37 0.53 0.08 0.02 3.26 0.94 3.37 2.64
Blood 1.06 0.09 0.10 0.02 2.07 0.41 1.74 0.69
Muscle 0.33 0.04 0.04 0.02 0.67 0.05 0.52 0.19
lung 108.84 19.07 5.19 1.67 25.75 3.27 37.46 5.92
liver 39.64 4.56 57.28 4.24 63.06 13.29 34.17 14.35
spleen 44.95 12.46 63.45 24.78 117.97 6.57 16.15 7.95
Kidney 4.13 0.57 0.62 0.06 8.68 1.32 10.59 3.37
Bladder 0.79 0.13 0.11 0.05 1.96 0.26 1.07 0.44
heart 2.06 0.21 0.21 0.04 2.81 0.44 2.08 0.86
Bone 0.95 0.21 0.46 0.11 2.12 0.31 1.28 0.50
Pancreas 0.97 0.13 0.14 0.05 1.86 0.36 1.30 0.53
stomach 1.43 0.49 0.44 0.16 2.63 0.32 1.70 0.82
Intestine 12.43 1.21 1.36 0.04 23.96 2.90 16.92 6.74
Notes: green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle.
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Table S3 Biodistribution of NP-NOTa-64cu in a431 tumor-xenografted mice after 24 hours
Organ NP1-NOTA-64Cu NP2-NOTA-64Cu NP3-NOTA-64Cu NP4-NOTA-64Cu
%ID/g ± SD %ID/g ± SD %ID/g ± SD %ID/g ± SD
Tumor 1.38 0.10 0.11 0.01 3.61 1.02 5.39 1.31
Blood 0.85 0.12 0.08 0.02 2.32 0.29 1.73 0.31
Muscle 0.35 0.08 0.03 0.09 0.83 0.08 0.69 0.15
lung 12.86 3.37 1.28 0.15 16.12 4.83 14.28 6.59
liver 31.11 5.72 52.95 2.68 44.74 4.04 26.02 4.96
spleen 26.66 4.04 77.02 18.71 63.01 23.13 9.13 1.60
Kidney 4.08 0.47 0.60 0.07 8.28 0.97 12.97 4.78
Bladder 0.89 0.23 0.12 0.06 1.85 0.38 1.72 1.05
heart 1.94 0.33 0.18 0.04 3.73 0.40 3.05 0.59
Bone 0.98 0.09 0.48 0.10 2.52 0.73 2.00 0.45
Pancreas 0.97 0.22 0.13 0.02 1.91 0.36 1.64 0.23
stomach 1.57 0.31 0.46 0.32 2.07 0.35 2.32 0.72
Intestine 8.10 1.01 0.82 0.08 17.05 1.97 13.12 2.02
Notes: green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle.
Table S4 Biodistribution of Pegylated NP-NOTa-64cu in a431 tumor-xenografted mice after 4 hours
Organ NP1-NOTA-PEG-64Cu NP2-NOTA-PEG-64Cu NP3-NOTA-PEG-64Cu NP4-NOTA-PEG-64Cu
%ID/g ± SD %ID/g ± SD %ID/g ± SD %ID/g ± SD
Tumor 0.84 0.27 0.18 0.03 2.72 0.51 4.11 1.06
Blood 0.64 0.09 0.20 0.04 1.49 0.21 1.33 0.06
Muscle 0.29 0.08 0.07 0.01 0.45 0.09 0.46 0.04
lung 126.06 14.51 25.41 5.91 34.74 8.67 36.54 5.93
liver 8.99 0.91 64.54 4.07 36.34 5.53 24.28 4.63
spleen 4.89 1.02 75.30 16.73 46.71 21.08 10.21 2.89
Kidney 2.93 0.31 1.93 0.07 5.80 1.20 7.26 2.09
Bladder 0.69 0.11 0.28 0.15 1.22 0.12 1.02 0.12
heart 1.41 0.08 0.73 0.06 2.10 0.35 2.04 0.20
Bone 0.53 0.13 0.93 0.31 1.79 0.34 1.18 0.18
Pancreas 0.75 0.07 0.30 0.15 1.22 0.33 1.31 0.22
stomach 1.12 0.20 1.43 0.60 1.84 0.46 1.86 0.38
Intestine 9.53 1.14 2.86 0.50 5.77 1.01 16.60 1.21
Notes: green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; Peg, Polyethylene 
glycol.
Table S5 Biodistribution of Pegylated NP-NOTa-64cu in a431 tumor-xenografted mice after 24 hours
Organ NP1-NOTA-PEG-64Cu NP2-NOTA-PEG-64Cu NP3-NOTA-PEG-64Cu NP4-NOTA-PEG-64Cu
%ID/g ± SD %ID/g ± SD %ID/g ± SD %ID/g ± SD
Tumor 0.84 0.33 0.15 0.05 2.70 0.67 5.05 1.30
Blood 0.56 0.27 0.11 0.03 1.34 0.33 1.35 0.08
Muscle 0.24 0.10 0.04 0.01 0.54 0.12 0.62 0.06
lung 20.23 5.72 2.11 0.38 16.59 6.92 14.89 5.78
liver 6.85 2.18 55.77 8.33 26.63 8.30 15.88 1.88
spleen 4.11 0.58 55.29 23.86 27.45 6.66 6.01 1.50
Kidney 2.53 0.88 1.11 0.17 5.29 1.14 7.11 0.72
Bladder 0.44 0.18 0.12 0.07 1.01 0.31 1.08 0.33
heart 1.19 0.37 0.25 0.05 2.53 0.70 2.77 0.38
Bone 0.57 0.18 1.03 0.18 1.77 0.48 1.52 0.30
Pancreas 0.64 0.24 0.15 0.03 1.26 0.32 1.57 0.11
stomach 0.90 0.28 0.30 0.14 1.24 0.47 2.16 0.43
Intestine 5.36 1.64 1.33 0.03 10.86 2.36 11.06 1.24
Notes: green: NP1, blue: NP2, red: NP3, orange: NP4. 
Abbreviations: 64cu, copper-64; %ID/g, percentage of injected dose per gram; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; Peg, polyethylene 
glycol.
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Table S6 Tumor-to-organ ratios of radiolabeled NPs in tumor-
xenografted mice
Sample TTB  
ratio ± SD
TTM 
ratio ± SD
NP1-NOTa-64cu: 4 hours 1.28±0.43 4.12±1.37
NP1-NOTa-Peg-64cu: 4 hours 1.31±0.34 2.95±0.49
NP1-NOTa-64cu: 24 hours 1.66±0.31 4.12±1.14
NP1-NOTa-Peg-64cu: 24 hours 1.56±0.25 3.55±0.47
NP2-NOTa-64cu: 4 hours 0.80±0.18 2.41±0.67
NP2-NOTa-Peg-64cu: 4 hours 0.92±0.21 2.53±0.21
NP2-NOTa-64cu: 24 hours 1.38±0.19 4.39±1.36
NP2-NOTa-Peg-64cu: 24 hours 1.35±0.14 4.32±1.41
NP3-NOTa-64cu: 4 hours 1.57±0.30 5.35±0.74
NP3-NOTa-Peg-64cu: 4 hours 1.85±0.46 6.17±0.87
NP3-NOTa-64cu: 24 hours 1.58±0.50 4.34±1.12
NP3-NOTa-Peg-64cu: 24 hours 2.04±0.32 4.98±0.75
NP4-NOTa-64cu: 4 hours 1.95±1.14 6.60±4.19
NP4-NOTa-Peg-64cu: 4 hours 3.08±0.76 9.03±2.79
NP4-NOTa-64cu: 24 hours 3.13±0.62 7.76±0.31
NP4-NOTa-Peg-64cu: 24 hours 3.77±1.02 8.12±1.40
Notes: green: NP1, blue: NP2, red: NP3, orange: NP4. 
Abbreviations: 64cu, copper-64; NOTa, 1,4,7-tricarboxymethyl-1,4,7-triazacy-
clononane; NP, nanoparticle; Peg, polyethylene glycol; TTB, tumor-to-blood; TTM, 
tumor-to-muscle.
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